Anti-TNF therapies--the hope of tomorrow (Q34999551)

5 August 2017

1 reference

title

Anti-TNF therapies--the hope of tomorrow (English)

1 reference

5 August 2017

0 references

0 references

Ronni Wolf

1

1 reference

5 August 2017

Hagit Matz

series ordinal

2

1 reference

5 August 2017

Edith Orion

series ordinal

3

1 reference

5 August 2017

Vincenzo Ruocco

series ordinal

4

1 reference

5 August 2017

publication date

1 September 2002

1 reference

5 August 2017

published in

Clinics in Dermatology

1 reference

5 August 2017

volume

20

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

522-530

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Tumor necrosis factor (TNF).

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Shock and tissue injury induced by recombinant human cachectin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The pathophysiology of tumor necrosis factors

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

TNF and Mae West or: death from too much of a good thing

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The tumor necrosis factor ligand and receptor families.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Tumor necrosis factor receptor genes, TNFR1 and TNFR2, on human chromosomes 12 and 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

1 reference

7 January 2021

The two different receptors for tumor necrosis factor mediate distinct cellular responses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Anti-TNF agents for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Infliximab treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The pilosebaceous unit is part of the skin immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Nickel and skin irritants up-regulate tumor necrosis factor-alpha mRNA in keratinocytes by different but potentially synergistic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

In situ changes in the relative abundance of human epidermal cytokine messenger RNA levels following exposure to the poison ivy/oak contact allergen urushiol

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Differential induction of cutaneous TNF-alpha and IL-6 by topically applied chemicals

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

TNF-alpha, RANTES, and MCP-1 are major chemoattractants of murine Langerhans cells to the regional lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

PRODUCTION AND IN SITU LOCALIZATION OF CUTANEOUS TUMOUR NECROSIS FACTOR α (TNF-α) AND INTERLEUKIN 6 (IL-6) FOLLOWING SKIN SENSITIZATION

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

IL-4 inhibits the migration of human Langerhans cells through the downregulation of TNF receptor II expression

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

1 reference

7 January 2021

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Molecular mechanism of ultraviolet-induced keratinocyte apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Growth factors and wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Epidermal signal transduction and transcription factor activation in activated keratinocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Keratinocyte-derived chemotactic cytokines: expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Quantitative analysis of proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in human skin wounds

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The immunologic and genetic basis of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Th1-Th2 paradigm: insights from leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

T cells involved in psoriasis vulgaris belong to the Th1 subset

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The treatment of psoriasis with IL-10: rationale and review of the first clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Identification of an inducible endothelial-leukocyte adhesion molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment of psoriatic arthritis with etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Clinical use of Infliximab in Crohn's disease: the Edinburgh experience

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Clinical features and treatment of peristomal pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Rapid response of severe refractory metastatic Crohn's disease to infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Infliximab for the treatment of orofacial Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Monoclonal anti-TNF-alpha suppresses graft vs host disease reactions in an in vitro human skin model

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Cytokine gene expression in skin and lymphoid organs in graft versus host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

The tissue expression of cytokines in human acute cutaneous graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900273-0

7 January 2021

10.1016/S0738-081X(02)00273-0

Identifiers

DOI

1 reference

5 August 2017

1 reference